250 related articles for article (PubMed ID: 29280483)
1. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.
Sanders DB; Juel VC; Harati Y; Smith AG; Peltier AC; Marburger T; Lou JS; Pascuzzi RM; Richman DP; Xie T; Demmel V; Jacobus LR; Aleš KL; Jacobus DP;
Muscle Nerve; 2018 Apr; 57(4):561-568. PubMed ID: 29280483
[TBL] [Abstract][Full Text] [Related]
2. Amifampridine Phosphate (Firdapse) Is Effective in a Confirmatory Phase 3 Clinical Trial in LEMS.
Shieh P; Sharma K; Kohrman B; Oh SJ
J Clin Neuromuscul Dis; 2019 Mar; 20(3):111-119. PubMed ID: 30801481
[TBL] [Abstract][Full Text] [Related]
3. Amifampridine for the Management of Lambert-Eaton Myasthenic Syndrome: A New Take on an Old Drug.
Yoon CH; Owusu-Guha J; Smith A; Buschur P
Ann Pharmacother; 2020 Jan; 54(1):56-63. PubMed ID: 31319693
[No Abstract] [Full Text] [Related]
4. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.
Raja SM; Sanders DB; Juel VC; Harati Y; Smith AG; Pascuzzi R; Richman DP; Wu A; Aleš KL; Jacobus LR; Jacobus DP; Guptill JT;
Muscle Nerve; 2019 Sep; 60(3):292-298. PubMed ID: 31269226
[TBL] [Abstract][Full Text] [Related]
5. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia.
Thakkar N; Guptill JT; Aleš K; Jacobus D; Jacobus L; Peloquin C; Cohen-Wolkowiez M; Gonzalez D;
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):625-634. PubMed ID: 28623849
[TBL] [Abstract][Full Text] [Related]
7. Treatment for Lambert-Eaton myasthenic syndrome.
Keogh M; Sedehizadeh S; Maddison P
Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
[TBL] [Abstract][Full Text] [Related]
8. Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.
Mantegazza R
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1013-1018. PubMed ID: 31639317
[No Abstract] [Full Text] [Related]
9. Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.
Oh SJ; Shcherbakova N; Kostera-Pruszczyk A; Alsharabati M; Dimachkie M; Blanco JM; Brannagan T; Lavrnić D; Shieh PB; Vial C; Meisel A; Komoly S; Schoser B; Sivakumar K; So Y;
Muscle Nerve; 2016 May; 53(5):717-25. PubMed ID: 26852139
[TBL] [Abstract][Full Text] [Related]
10. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
[TBL] [Abstract][Full Text] [Related]
11. Amifampridine to treat Lambert-Eaton myasthenic syndrome.
Oh SJ
Drugs Today (Barc); 2020 Oct; 56(10):623-641. PubMed ID: 33185628
[TBL] [Abstract][Full Text] [Related]
12. Amifampridine for the treatment of Lambert-Eaton myasthenic syndrome.
Oh SJ
Expert Rev Clin Immunol; 2019 Oct; 15(10):991-1007. PubMed ID: 31533480
[No Abstract] [Full Text] [Related]
13. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS.
Oh SJ; Claussen GG; Hatanaka Y; Morgan MB
Muscle Nerve; 2009 Nov; 40(5):795-800. PubMed ID: 19722254
[TBL] [Abstract][Full Text] [Related]
14. Reliability of the triple-timed up-and-go test.
Sanders DB; Guptill JT; Aleš KL; Hobson-Webb LD; Jacobus DP; Mahmood R; Massey JM; Pittman MM; Prather K; Raja SM; Yow E; Juel VC
Muscle Nerve; 2018 Jan; 57(1):136-139. PubMed ID: 28545168
[TBL] [Abstract][Full Text] [Related]
15. 3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Sanders DB
Ann N Y Acad Sci; 1998 May; 841():811-6. PubMed ID: 9668334
[No Abstract] [Full Text] [Related]
16. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study.
Wirtz PW; Verschuuren JJ; van Dijk JG; de Kam ML; Schoemaker RC; van Hasselt JG; Titulaer MJ; Tjaden UR; den Hartigh J; van Gerven JM
Clin Pharmacol Ther; 2009 Jul; 86(1):44-8. PubMed ID: 19357643
[TBL] [Abstract][Full Text] [Related]
17. Treatment for Lambert-Eaton myasthenic syndrome.
Maddison P; Newsom-Davis J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003279. PubMed ID: 15846654
[TBL] [Abstract][Full Text] [Related]
18. Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine.
Smith AG; Wald J
Neurology; 1996 Apr; 46(4):1143-5. PubMed ID: 8780107
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.
Sanders DB; Massey JM; Sanders LL; Edwards LJ
Neurology; 2000 Feb; 54(3):603-7. PubMed ID: 10680790
[TBL] [Abstract][Full Text] [Related]
20. 3,4-Diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis.
Sanders DB; Howard JF; Massey JM
Ann N Y Acad Sci; 1993 Jun; 681():588-90. PubMed ID: 8357206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
